Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

LENZ Therapeutics, Inc.

Make LNZ100 available for commercial launch

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
19 Mar 2025
Due
31 Dec 2025
Delivered
August 2025
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025”

What we found

Evidence strength A What the grades mean

The company launched its product VIZZ, formerly known as LNZ100, in August 2025, meeting the commitment to make the product available for commercial launch by the fourth quarter of 2025.

  • A
    LENZ Therapeutics, Inc. 10-Q filed 2026-05-11 Regulatory filing · published 11 May 2026 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 7e9cce0b843b
    “In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025.” ✓ confirmed on the page

Market reaction: the shares moved -20.6% against the S&P 500 over the three sessions around the disclosure (8 May 2026 to 13 May 2026). What this measures

Checked 2 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Commercial launch
Indicative materiality
Medium rules
Action
Make
Deliverable
LNZ100 product availability
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium
Conditional
Yes: Upon FDA approval
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2025-LENZ-003367 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.